Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Monday a definitive agreement to acquire CymaBay Therapeutics Inc (Nasdaq:CBAY), a clinical-stage biopharmaceutical company with a focus on liver and other chronic diseases that have high unmet medical need.
Under the terms of the agreement Gilead will acquire CymaBay for USD32.50 per share in cash, amounting to a total equity value of USD4.3bn.
This acquisition marks Gilead's expansion in the liver disease space, bolstering its portfolio with CymaBay's investigational lead product candidate, seladelpar, which is designed for treating primary biliary cholangitis (PBC), including pruritus.
PBC is a rare, chronic liver disease predominantly affecting women, with symptoms such as pruritus and fatigue significantly impacting patients' quality of life. Seladelpar, an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist, has demonstrated promising efficacy in regulating critical metabolic and liver disease pathways, earning FDA priority review status with approval anticipated in the third quarter of 2024.
The pivotal Phase 3 RESPONSE trial demonstrated seladelpar's superiority over placebo in achieving primary composite endpoints, including biochemical response and normalisation of alkaline phosphatase levels.
The transaction, approved by both companies' boards of directors, is expected to close in the first quarter of 2024, subject to regulatory approvals and customary closing conditions.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration